<qa>  What is the name of the phase I of the treatment?- Phase I: Patients receive tetra-O-methyl nordihydroguaiaretic acid EM-1421 IV on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. 